Skip to content
  • 6,807 federal solicitations are open right now. How many of them are yours?
  • New solicitations are posted every day. The ones you never saw are the ones you cannot win.
  • Stop checking SAM.gov every morning. Let the contracts that fit your business come to you.
  • Tell Abierto what you sell in one sentence. AI reads every open solicitation for you.
  • Deadlines are short. Hear about a solicitation the day it is posted, not the week it closes.
  • Amendments move deadlines. Watch a solicitation and Abierto tells you when it changes.
  • See which contracts in your field are about to end, and who holds them today.
  • Plans from $39 a month. See your matches before you pay.
See plans
AbiertoGet started
Menu

Sources sought

Oncology breast testing

HT001425SS0001

Defense Health Agency (Dha), Defense Health Agency. Medical Laboratories.

6 open like this View on SAM.gov Markdown

Response deadline

March 20, 2025 at 9:00 AM EDT

Closed 591 days ago. Posted February 21, 2025. Scheduled to archive April 4, 2025.

Get the next one like this from Defense Health Agency (Dha) by email, the day it is posted.Find my opportunities

This one closed in 2025

6 like it are open now in medical laboratories

All 6 open in medical laboratories

Description

As published on SAM.gov.

The Defense Health Agency (DHA), Northeastern Healthcare Operations Contracting Division (NEHO-CD), on behalf of AT. Augusta Military Medical Center, in support of the Pathology Department, Anatomic Section’s requirement for a source that provides testing for prognosis and prediction of chemotherapy.

The testing services are needed to conduct genetic molecular analysis to deliver relevant, diagnostic genetic and/or biological tumor information that enables ordering healthcare providers to optimize treatment protocols regarding potential breast, colon and prostate cancer types. The Oncotype DX ® test is identified as the only multigene assay that is both predictive of chemotherapy treatment effect and prognostic of disease outcome.

As such, this office intends to award a firm fixed price contract on a sole source basis to Genomic Health, Inc, 301 Penobscot Drive Redwood City CA 94063-4700, CAGE: 37AM2. However, if your company possesses the ability to provide a multigene assay that is both predictive of chemotherapy treatment effect and prognostic of disease outcome, provide this office with your company’s substantiated and validated information for further consideration.

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. February 21, 2025

    Sources sought

    Due March 20, 2025 at 9:00 AM EDT. SAM.gov, notice bbb24f12c8b44d629fa7c04a9fd56602

Points of contact